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Abstract
The protease beta-site APP cleaving enzyme 1 (BACE1) has fundamental functions 
in the nervous system. Its inhibition is a major therapeutic approach in Alzheimer's 
disease, because BACE1 cleaves the amyloid precursor protein (APP), thereby cata-
lyzing the first step in the generation of the pathogenic amyloid beta (Aβ) peptide. 
Yet, BACE1 cleaves numerous additional membrane proteins besides APP. Most 
of these substrates have been identified in vitro, but only few were further validated 
or characterized in vivo. To identify BACE1 substrates with in vivo relevance, we 
used isotope label-based quantitative proteomics of wild type and BACE1-deficient 
(BACE1 KO) mouse brains. This approach identified known BACE1 substrates, in-
cluding Close homolog of L1 and contactin-2, which were found to be enriched in 
the membrane fraction of BACE1 KO brains. VWFA and cache domain-containing 
protein 1  (CACHD)1 and MAM domain-containing glycosylphosphatidylinositol 
anchor protein 1 (MDGA1), which have functions in synaptic transmission, were 
identified and validated as new BACE1 substrates in vivo by immunoblots using 
primary neurons and mouse brains. Inhibition or deletion of BACE1 from primary 
neurons resulted in a pronounced inhibition of substrate cleavage and a concomitant 
increase in full-length protein levels of CACHD1 and MDGA1. The BACE1 cleav-
age site in both proteins was determined to be located within the juxtamembrane 
domain. In summary, this study identifies and validates CACHD1 and MDGA1 as 
novel in vivo substrates for BACE1, suggesting that cleavage of both proteins may 
contribute to the numerous functions of BACE1 in the nervous system.
K E Y W O R D S
gamma-secretase, inhibitory synapse, retina, secretase, SILAC
1 |  INTRODUCTION
Ectodomain shedding of membrane proteins is a basic cel-
lular process controlling the communication between cells, 
including in the brain.1 Upon shedding, the extracellular do-
main of a membrane protein is proteolytically cleaved off and 
released from cells. The contributing proteases, referred to as 
sheddases, are mostly themselves membrane-bound enzymes 
and often do not only cleave a single substrate, but numer-
ous different ones. Among the sheddases with multiple sub-
strates are rhomboids,2-4 a disintegrin and metalloproteases 
(ADAM),5-8 signal peptide peptidase-like 3 (SPPL3)9,10 and 
the beta-site APP cleaving enzymes (BACE) BACE111-15 and 
BACE2.12,16
Beta-site APP cleaving enzyme 1 was initially identified 
as the enzyme that cleaves the amyloid precursor protein 
(APP) at the β-secretase cleavage site.17 As a result, it sheds 
the APP ectodomain and catalyzes the first step in the gen-
eration of the amyloid beta (Aβ) peptide which is seen as a 
key pathogenic agent in the early steps of Alzheimer's dis-
ease (AD) pathogenesis.18 Thus, BACE1 inhibition is a major 
therapeutic approach for AD and several BACE1-targeting 
inhibitors have been advanced into phase 3 clinical trials.19 
However, several side effects were observed in some phase 
3 trials, such as psychiatric symptoms and increased falls,20-
22 which may be mechanism-based because BACE1 does 
not only cleave APP, but has multiple additional substrates 
with functions in the nervous system.23 Moreover, BACE1 
KO mice show several phenotypes, revealing a fundamental 
function for BACE1 in the nervous system. For several phe-
notypes, the contributing substrates have been identified. For 
example in mice, loss of BACE1 cleavage of neuregulin-1 
(NRG1) induces hypomyelination and defects in muscle 
spindle formation and maintenance.24-26 Loss of cleavage of 
seizure protein 6 (SEZ6) leads to defects in dendritic spine 
density and reduced long-term potentiation (LTP)27-29 and 
lack of cleavage of the close homolog of L1 (CHL1) re-
duces the length of the infrapyramidal bundle, an anatomical 
structure in the hippocampus,30,31 whereas loss of Jagged-1 
cleavage reduces neurogenesis and increases astrogenesis in 
mouse brain development.32 For several other phenotypes 
observed in BACE1 KO mice, such as memory deficits,33-36 
neurochemical deficits37 or postnatal lethality, and growth re-
tardation,38 the contributing substrate(s) are not yet known. 
   | 3NJAVRO et Al.
This is, at least partly, due to lack of knowledge, which ad-
ditional BACE1 substrates are relevant in vivo. While more 
than 40 BACE1 substrates have been identified, mostly in 
cell lines and primary neurons,11-14 only few of them were 
further validated or characterized in vivo.11,23,39
Thus, here we investigated BACE1 substrates in vivo, 
using the spike-in Stable Isotope Labeling with Amino acids 
(SILA) mouse technique combined with quantitative pro-
teomics and analyzed BACE1 KO brains. We identified sev-
eral known and new BACE1 substrates to be enriched in the 
brain membrane fractions of BACE1 KO mice. Furthermore, 
we validated the membrane proteins “MAM domain-con-
taining glycosylphosphatidylinositol anchor protein 1” 
(MDGA1) and “VWFA and cache domain-containing protein 
1” (CACHD1) as BACE1 substrates in vitro and in vivo and 
determined their cleavage site by BACE1, which was found 
to be located in the juxtamembrane domain at a short dis-
tance from the substrates’ transmembrane domain.
2 |  EXPERIMENTAL 
PROCEDURES
2.1 | Mouse strains
The following mouse strains were used: wild type (WT) 
C57BL/6 (Charles River, Wilmington, MA, USA), BACE1 
conditional knockout (BACE1 coKO; described below) and 
BACE1 KO (Jackson Laboratory, Bar Harbor, ME, USA, 
strain B6.129-Bace1tm1Pcw/J).40 These BACE1 KO mice 
were generated with the use of C57BL/6J blastocysts, with 
the chimeric animals being crossed to C57BL/6 mice, and 
then backcrossed for seven generations. Heavy labeled 
SILAC mouse brains (Lys 13C, 97%) were purchased from 
Silantes Gmbh, Munich, Germany. All animals were main-
tained with food and water ad libitum and on a 12/12 h light-
dark cycle. The procedures and protocols were in accordance 
with the European Communities Council Directive (86/609/
EEC) and approved by the Ludwig-Maximilians-Universität 
München and the government of Upper Bavaria.
2.2 | Membrane preparation of the brain
Mouse brains (200  mg) were homogenized in 1  mL high 
salt buffer (2 M NaCl, 10 mM HEPES/NaOH, pH 7.4, and 
1 mM EDTA, in ddH2O, supplemented with protease inhibi-
tor mix, 1:100, Roche) using a tissue homogenizer (Omni 
International, Kennesaw, GA, USA) at maximum speed for 
60  s and afterward centrifuged at 17 000 g for 15 minutes 
at 4°C (every washing step included the same centrifugation 
step). Cell pellet was washed two times with carbonate buffer 
(0.1 M Na2CO3, pH 11.3, and 1 mM EDTA, in ddH2O), once 
with urea buffer (5 M urea, 100 mM NaCl, 10 mM HEPES, 
pH 7.4, and 1 mM EDTA, in ddH2O) and two more times with 
Tris-HCl (0.1M TRIS/HCL, pH 7.6, in ddH2O). Membrane 
pellet was resuspended in 50 μL SDT-lysis buffer (2% (w/v) 
SDS, 100 mM TRIS/HCl pH 7.6, 0.1M DTT, in ddH2O) and 
incubated for 5 minutes at 95°C.
2.3 | Proteomic analysis of brain membrane 
fractions of BACE1 KO mice
For the proteomic analysis of the brain membrane fraction of 
BACE1 KO mice, the brains of BACE1 KO mice and their 
WT littermates at postnatal day 3 (P3) were dissected. In 
order to allow a P value–based statistical analysis of the data, 
three knockout and three WT mice were analyzed, all from 
the same litter that resulted from the mating of a heterozy-
gous BACE1 KO (−/+) male with a heterozygous BACE1 
KO (−/+) female. The brain tissue was homogenized in high 
salt buffer for membrane preparation as described above. In 
addition, P3 brains from mice stable isotope labeled by amino 
acids (SILA) with 13C lysine (Silantes Gmbh) were homog-
enized in the same buffer. After a protein assay, the homoge-
nates of SILA mouse brains were spiked into the samples of 
BACE1 KO and WT mice using a 1:1 protein ratio. The brain 
homogenates with the spike-in were subjected to membrane 
preparation as described above.
Membrane pellets were lysed in SDT buffer and 100 µg 
of proteins were subjected to filter aided sample preparation 
(FASP)41 as previously described with some modifications. 
Briefly, Vivacon 500 ultrafiltration columns with a cutoff of 
30 kDa (Sartorius, Goettingen, Germany) were used. Since 
spike-in brain samples were labeled with 13C lysine, only 
LysC was used for proteolytic digestion. Peptides were en-
riched and desalted using self-packed stop and go extraction 
(STAGE) tips with C18 material (EMPORE, 3M, Seefeld, 
Germany) as previously described.42 Peptides were dissolved 
in a 250 mM Britton and Robinson (B&R) buffer with a pH 
of 11 and a peptide fractionation was performed with SAX 
STAGE tips (Empore, 3M) as previously described.43 Briefly, 
six fractions were eluted using B&R buffers with pH 11, pH 
8, pH 6, pH 5, pH 4, and pH 3. Peptides were desalted again 
with C18 STAGE tips, dissolved in 0.1% formic acid and sub-
jected to liquid chromatography tandem mass spectrometry 
analysis (LC-MS/MS).
Two technical replicates were acquired for each of the 
peptide fractions and samples. For one biological replicate, 
the peptide yield was too low and only one technical replicate 
was measured. Peptides were separated on an in-house packed 
15 cm C18 column (ID: 75 µm, 2.4 µm Reprosil-Pur C18 AQ, 
Dr Maisch GmbH) using an Easy nLC II (Proxeon, part of 
Thermo Fisher Scientific, USA) nanoHPLC system with a bi-
nary gradient of water (A) and acetonitrile (B) supplemented 
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with 0.1% formic acid at a flow rate of 400 nL/min (0 min-
utes, 8% B; 145 minutes, 25% B; 227 minutes, 45% B). The 
LC was coupled online via a nano electrospray ion source to 
a LTQ Velos Pro Orbitrap mass spectrometer (Thermo Fisher 
Scientific, USA). Full MS spectra were acquired at a resolu-
tion 60 000 covering a scan range of 300-2000 m/z. The 14 
peptide ions with the highest intensities in each scan cycle 
were chosen for collision induced dissociation in the ion trap 
(min signal: 1000; isolation width: 2 m/z; normalized colli-
sion energy: 35%; activation q: 0.25; activation time: 10 ms; 
wideband activation applied). A dynamic exclusion of 120 s 
was applied for precursor selection.
The peptide cleavage assay was analyzed on an Easy nLC 
1000 nanoUHPLC coupled online to a Velos pro Orbitrap 
for MDGA1 and a Q-Exactive mass spectrometer (Thermo 
Fisher Scientific, USA) for CACHD1 using in-house packed 
30 cm C18 column (ID: 75 µm, 1.9 µm Reprosil-Pur C18 AQ, 
Dr Maisch GmbH). A gradient of 35 minutes at 250 nL/min 
and 50°C column temperature was applied. The Velos pro 
Orbitrap was used with similar setting as described above. 
The Q-exactive mass spectrometer was used with following 
settings: Full MS spectra were acquired at a resolution of 
70 000 covering a scan range of 300 to 1400 m/z. The 10 
peptides with the highest intensities were chosen for peptide 
fragmentation (automatic gain control: 5 E + 3 ions; isolation 
width: 2 m/z; maximum trapping time: 100-200 ms; resolu-
tion: 17 500).
2.4 | Proteomic data analysis
The data were analyzed with the software Maxquant (max-
quant.org, Max-Planck Institute Munich, Germany) version 
1.6.3.3.44 The MS data were searched against a reviewed 
canonical fasta database of Mus musculus from UniProt 
(download: November the 5th 2018, 17005 entries). Trypsin 
was defined as the protease. Two missed cleavages were al-
lowed for the database search. The option first search was 
used to recalibrate the peptide masses within a window of 
20 ppm. For the main search peptide and peptide fragment 
mass tolerances were set to 4.5 and 20  ppm, respectively. 
Carbamidomethylation of cysteine was defined as static 
modification. Acetylation of the protein N-term as well as 
oxidation of methionine was set as variable modifications. 
The false discovery rate (FDR) for both peptides and proteins 
was adjusted to less than 1%. The “match between runs” op-
tion was enabled with a matching window of 1.5  minutes. 
Relative quantification based on labeled lysine of proteins 
required at least one ratio counts of unique peptides. Only 
unique peptides were used for quantification.
To identify peptides of the peptide cleavage assay a data-
base search against the full-length peptides using unspecific 
cleavage was applied using Maxquant (version 1.5.3.12 or 
1.6.6.0). Peptides with a score higher than 40 were consid-
ered as potential hits. The peaks of the cleavage products and 
the full-length peptides were extracted in XCalibur to visual-
ize changes between incubation with recombinant BACE1, 
BACE1, and inhibitor C3, as well as incubation without 
BACE1.
2.5 | Statistical analysis
The protein quantification data of Maxquant was further pro-
cessed in Perseus.45 The normalized heavy to light protein 
ratios were log2 transformed. Afterwards, the log2 ratios of 
technical replicates were averaged and average protein log2 
fold changes were calculated between BACE1 KO and WT 
samples. A two-sided Student's t test was applied to evaluate 
the significance of proteins with changed abundance. In addi-
tion, permutation-based FDR estimation was used.46
Immunoblots of membrane fractions of the brain were 
performed with three additional biological replicates. 
Immunoblots of neurons were done using at least two differ-
ent neuronal preparations divided in up to six experiments 
for each condition within one preparation. This yielded 9 to 
16 independent experiments per each condition. Statistical 
testing was performed using Mann-Whitney U test with the 
significance criteria of P < .05.
2.6 | Western blotting and antibodies
To detect the soluble form of MDGA1, enrichment with 
Concanavalin A (ConA) beads (Sigma, Merck, Darmstadt, 
Germany; C7555) was used. According to the protein lysate, 
the amount of conditioned media was used for pull-down 
(sample with the lowest protein amount had maximum of 
900 μL of conditioned media) together with the 50 μL of pre-
washed ConA (washed two times in PBS). Each washing step 
included 5 minutes rotation at room temperature and centrif-
ugation step at 2500 g and 4°C. The samples were rotating 
overnight at 4°C, and then washed additional two times with 
PBS. For MDGA1, twenty-five microliters of nonreducing 
sample buffer (without β-mercaptoethanol) was added to the 
beads and incubated for 5 minutes, at 95°C. Other samples 
were diluted in regular Laemmli buffer and incubated for 
5 minutes at 95°C. For sample separation, 8% or 12% SDS-
polyacrylamide gels were used. Polyvinylidene difluoride 
(PVDF) transferred membranes were incubated with primary 
antibody overnight at 4°C, while the secondary antibody for 
1 hour at room temperature.
Primary antibodies used: APP (Millipore, Merck; 22C11, 
dilution 1:1000), BACE1 (Robert Vassar, Northwestern 
University, Chicago, IL, USA; 3D5, dilution 1:1000), CHL1 
(R&D Systems, Minneapolis, MN, USA; AF2147, dilution 
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1:1000), CNTN2 (R&D Systems; AF4439, dilution 1:1000), 
β-actin (Sigma, Merck; AC-74, A5316, dilution 1:1000), 
Calnexin (Enzo Life Sciences, Germany; ADI-SPA-860, di-
lution 1:1000), HA (Covance, Princeton, NJ, USA; MMS-
101P, dilution 1:1000), NrCAM (Abcam, Cambridge, UK; 
ab24344, dilution 1:1000), and SEZ6 (dilution 1:10 of pri-
mary hybridoma supernatant).47 Monoclonal anti-CACHD1 
antibody CACHI 15H10 (rat IgG1/k) (dilution 1:10 of primary 
hybridoma supernatant) was generated by immunization of 
Lou/c rats with the peptide NLENDRDERDDDSHEDR (in-
tracellular part of murine and human CACHD1) using stan-
dard procedures.48 Monoclonal anti-MDGA1 antibody DGA 
21E3 (rat IgG2a/k) (dilution 1:10 of primary hybridoma su-
pernatant) was generated by immunization of Lou/c rats with 
native recombinant, C-terminally BAP-HIS-tagged murine 
MDGA1 ectodomain spanning amino acids 20-925 which 
was lentivirally transduced and overexpressed in HEK293T 
via a Gal4-UAS expression system and purified via metal 
affinity chromatography. Secondary antibodies used: HRP-
coupled anti-goat (Santa Cruz, Heidelberg, Germany, sc-
2020, dilution 1:5000), anti-mouse (Promega, Mannheim, 
Germany, W402B, dilution 1:10 000), anti-rabbit (Promega, 
W401B, dilution 1:10 000) and anti-rat (Santa Cruz, sc-2006, 
dilution 1:5000).
2.7 | Preparation of primary mouse 
cortical and hippocampal neurons
Mouse cortical and hippocampal neurons were obtained from 
the embryonic day 16 cortex or hippocampus, cleaned from 
the meninges and collected in cold HBSS (Thermo Fisher 
Scientific, Darmstadt, Germany; 24020-091) as described.49,50 
Tissue was then incubated for 15 to 20 minutes at 37°C in di-
gestion medium (9.7 ml Dulbecco's Modified Eagle Medium 
(DMEM) high glucose with GlutaMAX Supplement (Thermo 
Fisher Scientific; 61965059), 0.01  g l-Cystein (Sigma, 
Merck; C6852), 200 U papain (Sigma, Merck; P3125), pH 
7.4, activated prior to use 30 minutes at 37°C). Tissue was 
dissociated either with 2 mL or 200 μL pipette in plating me-
dium (DMEM high glucose with GlutaMAX Supplement, 
10% FBS (v/v) (Thermo Fisher Scientific; 10270-106), 1% 
Penicillin/Streptomycin (5000 U/mL) (v/v) (Thermo Fisher 
Scientific; 15070-063)) for cortical or hippocampal culture, 
respectively. Dissociated cortical neurons were transferred to 
a new tube, pelleted at 700 g for 5 minutes, while dissociated 
hippocampal neurons were left for 30 seconds for the clumps 
to pellet by gravity and transferred the supernatant to the new 
tube. Both cell suspensions were counted, plated on the PDL 
coated dishes (25  μg/mL of PDL per well (Sigma, Merck; 
P6407)) and cultured at 37°C, 5% CO2. Plating medium 
was exchanged for culturing medium (9.6  mL Neurobasal 
(Thermo Fisher Scientific; 21103049), 500  μM GlutaMAX 
supplement (Thermo Fisher Scientific; 35050061), 1% 
Penicillin/Streptomycin (5000 U/mL) (v/v), 1 × B27 supple-
ment (Thermo Fisher Scientific; 17504044)) after 3-4 hours.
2.8 | Treatment and collection of primary 
mouse cortical neurons
BACE1 conditional knockout (BACE1 coKO) neurons were 
transduced with lentiviruses (Codon-optimized Cre recombi-
nase iCre or control GFP in a pF2U vector; virus purified as 
described51) at day 2 in vitro (DIV). Ubiquitous expression of 
iCre targets the loxP sites of the floxed BACE1 allele caus-
ing excision of exon 2 and subsequent knockout of BACE1 
in neurons (Figure S2A). At DIV  4, neurons were washed 
twice with PBS and finally collected at DIV 6. For the experi-
ments with additional treatment, for both WT and BACE1 
coKO, neurons were washed at DIV 5 and 2 μM C3 (BACE1 
inhibitor IV, Calbiochem, Merck; 565788), 1  μM DAPT 
(γ-secretase inhibitor, Sigma, Merck; D5942), or DMSO 
(control; an equal amount of dissolvent was used to maintain 
the homogeneity of the experimental conditions) was added 
and finally collected at DIV 7. Collection was done by lys-
ing the neurons in STET-lysis buffer with protease inhibi-
tor (150 mM NaCl, 50 mM Tris (pH 7.5), 2 mM EDTA, 1% 
Triton X-100). For electrophysiology, hippocampal neurons 
between DIV 12 and DIV 15 were grown on a coverslip and 
pretreated overnight with 2 μM C3 or DMSO.
2.9 | Generation of conditional BACE1 KO 
(BACE1coKO) mice
For homologous recombination in IDG3.2 cells a EUCOMM 
based vector was used that contained loxP-flanked exon 2 
of the Bace1 gene. The targeting vector was linearized by 
SalI and used for homologous recombination in embryonic 
stem (ES) cells (cell line IDG3.2-rosa26 established from 
(C57BL/6J 3129S6SvEvTac)-F1 blastocysts52) as previ-
ously described.53 IDG3.2-rosa26 ES cells were cultured 
on gelatine-coated cell plates in Standard DMEM contain-
ing sodium pyruvate, 15% FCS, 24 μM HEPES, 1 × MEM 
nonessential amino acids, 120 μM β-mercaptoethanol and 
leukemia inhibitory factor (LIF) (1.8  ×  103 U/mL). ES 
cells were maintained in a 37°C incubator with humidi-
fied atmosphere of 20% O2 and 5% CO2. After electropo-
ration, 150 clones were isolated, individually expanded 
and analyzed for homologous recombination. Eight posi-
tive ES cell clones were expanded, and one ES cell clone 
(Bace-E8) was used for microinjection into BALB/c blas-
tocysts yielding seven chimeric animals. Four of these 
were backcrossed with C57BL/6J mice and all of them 
successfully transmitted the conditional Bace-1 knockout 
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allele to the germ line. In order to remove the SA-IRESlacz 
and β-actin promoter-neomycin selectable marker cassettes 
that are surrounded by flip recombinase target (FRT) sites, 
the mice were crossed with the flippase (FLP) recombinase 
containing mice (Tg(ACTFLPe)9205Dym MGI:2448985) 
(as can be seen in Figure S2). FLP recombination be-
tween FRT sites excises the two cassettes to generate the 
floxed allele of the BACE1 gene exon 2, thus producing 
the BACE1 coKO mice. Genotypes of mice were veri-
fied by ear biopsies DNA polymerase chain reaction (PCR) 
using primers: 5´-AGGTGTGTGTGGGACTCCAT-3´, 
5´-AGGTGTGTGTGGGACTCCAT-3´ and 5´-AGGTGTG 
TGTGGGACTCCAT-3´ to control the BACE1 FRT con-
ditional knockout, 5`-AGGTGTGTGTGGGACTCCAT-3´, 
5´-AGGTGTGTGTGGGACTCCAT-3´ for the floxed BACE1 
allele and 5´-CTCGAGGATAACTTGTTATTGC-3´, and 5´- 
CTAATGTTGTGGGAAATTGGAGC-3´ for the FLP allele.
2.10 | In vitro cleavage assay
The murine peptides (MDGA1––PINPSGPFQIIFEGVRG 
SGY, CACHD1––KSPYVDDMGAIGDEVITL, Peps4LS 
GmbH, Heidelberg, Germany) were dissolved in 40% 
acetonitrile at a concentration of 1  mg/mL. Recombinant 
BACE1 was preincubated in 50 mM sodium acetate buffer 
pH 4.4 with or without C3 inhibitor for 15 minutes, at 37°C. 
An amount of 5 µg of peptides was added to buffer without 
or with recombinant BACE1, as well as BACE1 and C3 in-
hibitor. The reaction mixtures were incubated overnight at 
37°C. Digested samples were added to the mixture of Sera-
Mag SpeedBeads A and Sera-Mag SpeedBeads B (1:1 ratio, 
Thermo Fisher Scientific, Waltham, MA, USA) and 95% 
acetonitrile. Samples were centrifuged for 18  minutes at 
1000 rpm and room temperature and subsequently washed 
two times with 100% acetonitrile. Between each wash sam-
ples were centrifuged shortly at 16  000  g and placed in 
a magnetic rack. Elution was done with 2% DMSO and 
the samples were sonicated two times 30  seconds in the 
water bath. Samples were collected by short centrifugation 
at 16 000 g and separated from the beads using magnetic 
rack. Peptides were acidified to a final concentration of 1% 
formic acid for mass spectrometric analysis.
Peptides were separated on an in-house packed 30 cm 
C18 column (ID: 75  µm, 2.4  µm Reprosil-Pur C18 AQ, 
Dr Maisch GmbH, Ammerbuch, Germany) using an Easy 
nLC 1000 (Thermo Fisher Scientific, USA) nanoHPLC 
system with a binary gradient of water (A) and acetoni-
trile (B) supplemented with 0.1% formic acid at a flow 
rate of 250 nL/min (0 minutes, 8% B; 145 minutes, 25% 
B; 227  minutes, 45% B). The LC was coupled online 
via a nano electrospray ion source to a Q-Exactive mass 
spectrometer (Thermo Fisher Scientific, USA). Full MS 
spectra were acquired at a resolution of 70 000 covering 
a scan range of 300 to 1400 m/z. The 10 peptide ions with 
the highest intensities in each scan cycle were chosen for 
higher energy collisional induced dissociation (min signal: 
5E + 4; isolation width: 2 m/z; normalized collision en-
ergy: 25%). A dynamic exclusion of 3 seconds was applied 
for precursor selection to get multiple fragment ion spectra 
of the cleavage products.
2.11 | Preparation and cultivation of brain 
slice cultures
Entorhino-hippocampal tissue cultures were prepared at 
postnatal day 4-5 from C57BL/6J mice of either sex as de-
scribed previously.54 Cultivation medium contained 50% 
(v/v) MEM, 25% (v/v) basal medium eagle, 25% (v/v) heat-
inactivated normal horse serum, 25  mM HEPES buffer 
solution, 0.15% (w/v) bicarbonate, 0.65% (w/v) glucose, 
0.1  mg  mL-1 streptomycin, 100 U mL-1 penicillin, and 
2 mM glutamax. The pH was adjusted to 7.3, and the me-
dium was replaced three times per week. All slice cultures 
were allowed to mature for at least 18 days in humidified 
atmosphere with 5% CO2 at 35°C. Tissue cultures were 
treated for 3 days with 2 µM C3 or DMSO before experi-
mental assessment.
2.12 | Electrophysiological recordings of 
GABAergic miniature inhibitory postsynaptic 
currents (mIPSCs) from dissociated mouse 
primary hippocampal neurons
Mouse primary hippocampal neurons were whole-cell 
voltage-clamped at −70 mV using EPC10 USB amplifier 
(HEKA Electronics, Lambrecht/Pfalz, Germany). The ac-
quisition interface was controlled by using Patch master 
program (HEKA Electronics). In all experiments the fol-
lowing solutions were used: extracellular solution (140 mM 
NaCl, 2.4 mM KCl, 10 mM Hepes, 10 mM glucose, 4 mM 
CaCl2, and 4 mM MgCl2, 320 mOsmol/L, pH 7.4); patch-
pipette solution (136  mM KCl, 17.8  mM Hepes, 1  mM 
EGTA, 0.6 mM MgCl2, 4 mM NaATP, 0.3 mM Na2GTP, 
15 mM creatine phosphate, and 5 U/mL phosphocreatine 
kinase, 310-320 mOsmol/L, pH 7.4). Miniature inhibitory 
postsynaptic currents (mIPSCs) were recorded in the pres-
ence of 300 nM tetrodotoxin (TTX) and 10 μM 2,3-dihy-
droxy-6-nitro-7-sulfamoyl-benzo (F)quinoxaline (NBQX). 
Except for TTX (Purchased from Abcam), all chemicals 
were purchased from Sigma. Data were analyzed using 
Axograph X version 1.6.5. Further data analysis/visualiza-
tion was performed by using Graph Pad Prism 7 and Adobe 
illustrator version CS5.1.
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2.13 | Electrophysiological recordings of 
GABAergic mIPSCs from CA1 pyramidal 
neurons of entorhino-hippocampal 
tissue cultures
Whole-cell voltage-clamp recordings were carried out at 
35°C. The bath solution contained 126 mM NaCl, 2.5 mM 
KCl, 26  mM NaHCO3, 1.25  mM NaH2PO4, 2  mM CaCl2, 
2 mM MgCl2, and 10 mM glucose. Patch pipettes contained 
40 mM CsCl, 90 mM K-gluconate, 1.8 mM NaCl, 1.7 mM 
MgCl2, 3.5  mM KCl, 0.05  mM EGTA, 2  mM ATP-Mg, 
0.4 mM GTP-Na2, 10 mM PO-Creatine, and 10 mM HEPES 
(pH = 7.25 with KOH, 290 mOsm with sucrose) having a 
tip resistance of 4-6 MΩ. Neurons were recorded at a hold-
ing potential of −70  mV in the presence of 0.5  µM TTX, 
10 µM CNQX, and 10 µM APV. Series resistance was moni-
tored in 2 minutes intervals, and recordings were discarded 
if leak current or series resistance changed significantly 
and/or reached ≥30 MΩ or ≥350 pA, respectively. Data 
were analyzed using pClamp 10.2 (Axon Instruments) and 
MiniAnalysis (Synaptosoft) software.
2.14 | Immunofluorescence
For immunofluorescence labeling, COS7 cells were cultured 
for 48h in DMEM supplemented with 10% fetal calf serum 
(FCS), 1% Penicillin-Streptomycin (Pen/Strep), and seeded 
onto PDL-coated glass coverslips. Cells were fixed with 4% 
paraformaldehyde in 4% sucrose solution for 10  minutes at 
room temperature and unfixed cells were washed three times 
with 1x phosphate-buffered saline (PBS). Cells were quenched 
with 50 mM ammonium chloride for 10 minutes at room tem-
perature and washed three times with 1x PBS. Afterward, cells 
were incubated with 0.1% Triton X in 1x PBS for 10 minutes 
and washed three times with 1x PBS. Afterward, cells were 
blocked in 2% FCS, 2% bovine serum albumin (BSA), 0.2% 
Fish Gelatin in 1x PBS for 1h at room temperature and in-
cubated over night at 4°C with anti-EEA1 (species: mouse, 
dilution 1:200), anti-KDEL (species: mouse, dilution 1:200), 
or anti-Giantin (species: mouse, dilution 1:200) followed by 
1h incubation at room temperature with directly fluorophore-
coupled anti-GFP-488 (species: rabbit, dilution 1:500, against 
CACHD1-GFP) and secondary antibody anti-mouse-555 (di-
lution 1:500) for the three organelle marker primary antibodies. 
Before and after antibody incubation cells were washed three 
times with 1x PBS. Nuclei were stained with Hoechst (dilution 
1:2000) for 30 minutes at room temperature. Coverslips were 
mounted in FluorSave (Calbiochem, Merck) onto glass slides 
and imaged with confocal microscopy using a Leica TCS SP5 
Confocal Laser Scanning Microscope (LSM) or Zeiss LSM 
510 Axio Observer (Zeiss, Munich, Germany). Pictures were 
processed with Photoshop (Adobe) or ZEN2 (Zeiss).
2.15 | Deglycosylation assay
Cortical neuronal lysate was treated with endoglycosidase H 
(Endo H, New England Biolabs, Frankfurt am Main, Germany; 
P0702), or Peptide-N-Glycosidase (PNGase F, New England 
Biolabs; P0704) according to the manufacturer's protocol and 
separated on 8% or 12% SDS-polyacrylamide gel.
2.16 | Retina preparation, histology, and 
immunohistochemistry
Retinas were dissected at 4 months of age and further pro-
cessed as described for immunohistology.55 Ten micrometer 
thick retinal cross sections were processed for hematoxy-
lin and eosin staining or for immunohistochemistry. Cy3-
coupled mouse monoclonal anti-GFAP (Sigma, Merck) 
was added overnight at a dilution of 1:1000. Nuclei were 
counterstained with Hoechst 33342. The examined area was 
determined microscopically by a Leica LSM 510 Meta con-
focal scan microscope (Zeiss) or a conventional fluorescence 
microscope (Nikon Eclipse). Quantification of outer nuclear 
layer thickness was done from images taken from representa-
tive central areas from 12 retinal cross sections per biological 
replicate (n = 3 per genotype).
3 |  RESULTS
3.1 | Proteomic analysis of BACE1 KO 
mouse brains
For BACE1 substrate identification in vivo, we used brains 
of WT and BACE1 KO mice from P3 when BACE1 pro-
tein abundance is high compared to adult mice.25 BACE1 
substrates are transmembrane or glycosylphosphatidylino-
sitol (GPI)-anchored membrane proteins, and inhibition 
or knockout of BACE1 often leads to an accumulation of 
BACE1 substrates on the cell surface of BACE1-expressing 
cells, in particular neurons.11,14,47 Thus, we scored mem-
brane proteins as in vivo BACE1 substrate candidates if their 
protein levels in the brain membrane fraction were increased 
upon knockout of BACE1. The soluble brain fraction was 
not analyzed, as it does not only contain the extracellular 
cleavage products of BACE1 substrates, but also the much 
more abundant cytosolic proteins, which interfere with the 
detection of the low-abundant BACE1 substrates. In order 
to accurately monitor even small changes in the membrane 
proteome of the brain, a spike-in of mouse brain tissue with 
Stable Isotope Labeling by Amino acids (SILA) combined 
with a quantitative proteomic workflow was used (Figure 
1A). Brains from commercially available SILA 13C lysine-
labeled P3 WT mice were used as reference brain tissue, 
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where all proteins contain lysines labeled with six heavy 13C 
isotopes. These reference brains were mixed (spike-in ap-
proach) with brain tissue from our unlabeled mice, either 
WT or BACE1 KO, and further processed for mass spectro-
metric analysis, including the LysC digestion. The protease 
LysC cleaves proteins at the C-term of lysines. Thus, all 
peptides derived from the SILA spike-in possess at least one 
heavy labeled lysine, which introduces a mass shift of 6 Da 
in comparison to the peptides originating from unlabeled 
WT or BACE1 KO samples. Eventually, a duplet of peptide 
signals with unlabeled and heavy labeled lysines is detected 
by mass spectrometry and is used for relative quantification 
of proteins (Figure 1A). This method allows a normalization 
of all peptide intensities from WT or BACE1 KO samples to 
the corresponding heavy reference peptides of the spike-in, 
yielding the ratios WT/reference and BACE1 KO/reference 
for relative protein quantification. The MS data analysis 
software Maxquant reports heavy to light protein ratios. For 
relative quantification, ratios were inverted to obtain WT 
(light) and BACE1 KO (light) to reference (heavy) ratios 
which allowed to calculate average KO to WT protein ra-
tios and to perform a statistical evaluation of protein abun-
dance changes. The normalization of protein intensities to 
the spike-in minimizes quantification inaccuracies due to 
membrane preparations, extensive peptide fractionation, and 
LC-MS/MS performance over several days of measurement.
F I G U R E  1  BACE1 substrate identification in vivo. A, Proteomic workflow of the Stable Isotope Labeling by Amino acids (SILA) spike-in 
approach. Isotopically heavy (13C6) labeled mouse brain tissue was combined with unlabeled (light) mouse brain tissue from wild-type (WT) or 
BACE1 KO mice. WT and BACE1 KO mice were littermates. B, Volcano plot of membrane fractions of BACE1 KO and WT mouse brains. The 
negative log10 transformed P value (y-axis) is plotted against the mean protein log2 fold change (x-axis) between BACE1 KO and WT samples. 
Single-span transmembrane proteins and GPI-anchored proteins are colored in blue. The hyperbolic curves represent a permutation-based FDR 
correction for multiple hypotheses. Proteins above the FDR curve remain significantly changed after FDR correction. C, Western blot analysis 
of the membrane preparation of WT, and BACE1 KO mouse brains at P3 shows accumulation of full-length CNTN2, CHL1, APP, MDGA1, 
and CACHD1. D, Statistical analysis was performed with n = 8 biological replicates using Mann-Whitney U test with the significance criteria of 
P < .05. All proteins accumulate significantly, except for CACHD1 that shows a nonsignificant trend to an increase. Graphs are presented with 
mean ± SEM
(D)(C)
(B)(A)
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Membrane fractions from three biological replicates 
(WT and BACE1 KO brains) were proteomically analyzed. 
Overall, 2932 proteins were relatively quantified in at least 
two biological replicates. This included proteins that are an-
notated in Uniprot as integral membrane proteins or mem-
brane-associated proteins, but also soluble proteins which 
are likely to bind to integral or membrane-associated pro-
teins. BACE1 substrates are usually single-span transmem-
brane proteins with type 1 (TM1) topology or GPI-anchored 
proteins, but can also have a TM2 topology. Here, we have 
relatively quantified 1064 transmembrane or GPI-anchored 
proteins, which contain 464 single-pass or GPI-anchored 
proteins (Data S1).
The membrane proteins were scored as BACE1 substrate 
candidates if their level increased by at least 30% (vertical 
dotted line in the volcano plot in Figure 1) and if the change 
reached a significance of less than 0.05 using a two sample 
Student's t test (corresponding to a value higher than 1.3 on 
the logarithmic y-axis, Figure 1B). This led to 10 transmem-
brane or GPI-anchored proteins being identified as potential 
BACE1 substrates, including the known BACE1 substrates 
APP17 (1.47-fold increase), APLP256,57 (1.59-fold), CNTN211 
(3.90-fold), and CHL111,30 (2.76-fold), which validated our 
proteomic screening approach. Furthermore, we observed an 
accumulation for the transmembrane type I protein CACHD1 
(1.32-fold), which is a suggested BACE1 substrate candi-
date,11,13 and the GPI-anchored protein MDGA1 (MAM do-
main-containing glycosylphosphatidylinositol anchor protein 
1) (1.44-fold), which is a novel BACE1 substrate candidate. 
Additionally, we found increased protein levels of the trans-
membrane or GPI-anchored proteins PCDHGA4 (1.37-fold) 
and GLG1 (1.33-fold), which are suggested BACE1 substrate 
candidates,11-14 and of SEMA4A (1.78-fold), and GPC4 
(1.34-fold), which are new potential BACE1 substrates. Thus, 
the proteomic analysis identified known BACE1 substrates or 
candidates as well as new BACE1 substrate candidates.
In addition, thirteen soluble or mitochondrial proteins were 
found to be enriched in the KO samples. Two mitochondrial 
multi-pass transmembrane proteins, NNT and SLC25A31, 
were found with an increased abundance. Moreover, 10 sol-
uble proteins, namely NEFM, INA, PSIP1, AHI1, NAP1L4, 
VIM, GNAL, MYL6, ATIC, and GPI, were detected with a 
higher abundance in the KO samples. Because so far known 
BACE1 substrates are exclusively membrane proteins and 
BACE1 is localized in the TGN and endosomes, it is likely 
that the identified soluble and mitochondrial proteins do not 
constitute BACE1 substrates but were enriched as an indi-
rect consequence of BACE1-deficiency. Three proteins were 
reduced in the BACE1 KO brains (NLRX1, ABAT, and 
BACE1). The reduction of BACE1 in the BACE1 KO brains 
was expected. The low amount of still detected BACE1 in the 
KO brains is most likely the result of a small carry-over effect 
between KO and WT LC-MS/MS runs.
Next, we validated the mass spectrometric measure-
ments using immunoblots as a different method. Similar to 
the proteomic experiments, membrane fractions were gener-
ated from BACE1 KO and WT mouse brains. In agreement 
with the proteomic mouse brain data, the full-length levels 
of both MDGA1 and CACHD1 showed a mild increase in 
the BACE1 KO membrane fractions (Figure 1C,D), while the 
levels of the soluble MDGA1 and CACHD1 ectodomains in 
the soluble brain fraction were below the detection limit, pre-
sumably, because this soluble fraction does not only contain 
the extracellular cleavage products of BACE1 substrates, but 
also the much more abundant cytosolic proteins. Full-length 
levels were also increased for the two established BACE1 
substrates CNTN2 and CHL1 (Figure 1C,D).
3.2 | Validation of MDGA1 and CACHD1 as 
BACE1 substrates
Next, we validated whether CACHD1 and MDGA1 are in-
deed substrates of BACE1 or if their accumulation is a conse-
quence of secondary effects due to BACE1 deletion. To this 
aim, we monitored whether BACE1 inhibition abolishes the 
occurrence of a cleavage product of the substrates. CACHD1 
was chosen as it had the smallest fold change (1.32) of the 
substrate candidates and was previously identified as a po-
tential substrate in other proteomic studies,11,13 but was not 
yet validated. MDGA1 was chosen because it had the best 
significance value of the substrate candidates and because it 
is a novel BACE1 substrate candidate.
Both MDGA1 and CACHD1 are membrane proteins 
with a topology that potentially allows cleavage by BACE1. 
MDGA1 is a GPI-anchored protein and has six Ig-like, a fi-
bronectin type-III and a MAM domain (Figure 2A). In con-
trast, CACHD1 is a single-pass type 1 membrane protein with 
two Cache and one VWFA domain (Figure 3A). As it was 
not yet studied molecularly at the beginning of our study, we 
tagged CACHD1 with a C-terminal GFP-tag and found that it 
indeed localized to cellular membranes in transfected COS7 
cells, as expected for a transmembrane protein (Figure S1). 
We observed a localization to the plasma membrane and the 
Golgi and partly to the endoplasmic reticulum and endo-
somes, in agreement with two very recently published studies 
on CACHD1.58,59
Validation of MDGA1 and CACHD1 as BACE1 sub-
strates was done using primary murine neurons, where 
BACE1 was either pharmacologically or genetically inac-
tivated. For the pharmacological inhibition, neurons were 
treated with a BACE1 inhibitor (BI, either BACE1 inhibitor 
C360 - also known as BACE1 inhibitor IV - or LY288672161) 
or DMSO as a control. The non-cleaved, full-length pro-
teins MDGA1 and CACHD1 were detected by immuno-
blots in the cell lysate (Figures 2B and 3B), where both 
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proteins showed an about 1.2-fold enrichment upon BACE1 
inhibition, in agreement with the proteomic data (Figure 
1). The BACE1-cleaved soluble ectodomain of MDGA1 
(sMDGA1) was detected in the conditioned medium and 
was reduced to 30% upon BACE1 inhibition (Figure 2B), 
in line with MDGA1 being a new BACE1 substrate and no 
longer being efficiently processed upon BACE1 inhibition. 
For CACHD1, no antibody was available for detection of 
the endogenous BACE1-cleaved soluble ectodomain (sCA-
CHD1). Thus, we detected the other fragment arising from 
BACE1 cleavage, namely the CACHD1 C-terminal frag-
ment (CTF), which was detected in the neuronal cell lysate 
(Figure 3B). As CACHD1 is a type I membrane protein, 
its CTF may potentially be further cleaved by γ-secretase 
after the initial BACE1 cleavage, which would be similar 
to APP.62-64 In fact, similar to what is known for APP we 
detected the CACHD1 CTF only after pharmacological 
inhibition of γ-secretase with DAPT,65 demonstrating that 
CACHD1 is also a substrate for γ-secretase. Importantly, the 
CACHD1 CTF was no longer seen upon additional inhibi-
tion of BACE1, revealing that CACHD1 is indeed a sub-
strate for BACE1 (Figure 3B).
Next, genetic inactivation of BACE1 was used and the 
full-length proteins and their cleavage products were again 
detected by immunoblots. We generated conditional BACE1 
KO mice (BACE1 coKO) (Figure S2) and prepared primary 
cortical neurons that were treated with control (GFP) virus 
(keeping BACE1 expression) or iCre virus (inducing BACE1 
KO) at day 2 in vitro (DIV 2). Cell lysates and conditioned 
media were collected at DIV 6 to DIV 7 to provide enough 
time for the deletion of BACE1, which was successfully 
achieved (immunoblot in Figures 2C and 3C). For CACHD1, 
the γ-secretase inhibitor DAPT was additionally applied at 
DIV 5 to detect the CACHD1 CTF. Similar to BACE1 in-
hibitor-treated neurons, MDGA1 full-length protein was sig-
nificantly increased in total cell lysates, accompanied by a 
strong reduction of its shed ectodomain in the conditioned 
media upon BACE1 deletion (Figure 2C). Likewise, full-
length CACHD1 accumulated in the total cell lysates, while 
the levels of the CACHD1 CTF were clearly decreased in the 
iCre infected BACE1 coKO neurons (Figure 3C).
In order to not only detect the CACHD1 CTF, but also 
the other cleavage products arising from BACE1 cleav-
age––sCACHD1––we overexpressed CACHD1 with an 
F I G U R E  2  Validation of MDGA1 as BACE1 substrate in primary neurons. A, Schematic domain structure representation of MDGA1. The 
number of amino acids (aa) in each domain is indicated. B, Primary cortical neurons from WT mice were treated with BACE1 inhibitor (BI) 
or DMSO as a control. MDGA1 full-length protein (MDGA1) was mildly increased in total lysates, whereas its cleaved, soluble ectodomain 
(sMDGA1) in the conditioned medium was reduced upon BACE1 inhibition (labeled with arrowhead). Data were analyzed using Mann-Whitney 
U test with the significance criteria of P < .05 and are shown relative to the control (ctr) condition with DMSO. C, BACE1 coKO neurons were 
treated with iCre virus to induce BACE1 KO or with GFP virus to maintain BACE1 expression. MDGA1 accumulated upon BACE1 deletion in 
total cell lysates of BACE1 conditional knockout neurons, whereas the soluble ectodomain of MDGA1 (sMDGA1) was significantly reduced in the 
conditioned medium applying Mann-Whitney U test with the significance criteria of P < .05. Graphs are presented with mean ± SEM
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N-terminal HA-tag in primary cortical neurons using a 
lentivirus system. As expected, full-length CACHD1 ac-
cumulated in total lysates whereas its shed ectodomain 
(sCACHD1, detected with an anti-HA antibody) was al-
most abolished in conditioned media upon inhibition of the 
endogenous neuronal BACE1 (Figure 3D). Taken together, 
the pharmacological and genetic experiments as well as 
the proteomic experiments in Figure 1 demonstrate that 
MDGA1 and CACHD1 are BACE1 substrates both in vitro 
and in vivo.
3.3 | Determination of cleavage sites in 
MDGA1 and CACHD1
Sheddases often cleave their substrates within the ectodo-
main at a short distance from the beginning of the trans-
membrane domain in the so-called juxtamembrane domain. 
This is also seen for different BACE1 substrates, such as 
APP,17 SEZ6L,11 and SEZ6.47 To determine the cleavage 
sites of BACE1 within the juxtamembrane domains of 
MDGA1 and CACHD1, an in vitro assay was performed. 
F I G U R E  3  Validation of CACHD1 as BACE1 substrate in primary neurons. A, Schematic domain structure representation of CACHD1. The 
number of amino acids (aa) in each domain is indicated. B, Validation of CACHD1 in WT cortical neurons, treated with γ-secretase inhibitor 
(DAPT), BACE inhibitor (BI), a combination of DAPT and BI or solvent control (DMSO). CACHD1 full-length (CACHD1 fl) protein was 
significantly accumulated in the cell lysate upon BACE1 inhibition using Mann-Whitney U test with the significance criteria of P < .05. The 
short-lived CACHD1 C-terminal fragment (CACHD1 CTF, labeled with arrowhead) was detected in the lysate upon inhibition of γ-secretase with 
the inhibitor DAPT. Its generation was blocked, when BACE1 was additionally inhibited with BI. C, BACE1 coKO neurons were treated with 
iCre or GFP control lentivirus to induce BACE1 KO or WT condition, respectively. CACHD1 fl significantly accumulated upon BACE1 deletion 
in total cell lysates applying Mann-Whitney U test with the P value less than .05. CACHD1 CTF was detected in the lysate with DAPT treatment. 
Its generation was blocked, when BACE1 was knocked-out. D, To detect the soluble ectodomain of CACHD1 (sCACHD1), which is released 
from cells after BACE1 cleavage, primary cortical neurons were transduced with a CACHD1 lentivirus construct having an N-terminal HA- and 
a C-terminal FLAG epitope tag. In addition, neurons were treated with BACE1 inhibitor (BI) or DMSO as a control. Upon BACE1 inhibition 
CACHD1 fl protein significantly accumulated in the neuronal lysate (detected with anti-CACHD1 antibody), whereas release of its ectodomain 
(sCACHD1, detected with anti-HA antibody) into the conditioned medium was largely abolished. Mann-Whitney U test was used to determine 
significance criteria of P < .05. All graphs are presented with mean ± SEM
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We incubated peptides of the juxtamembrane regions of 
MDGA1 (PINPSGPFQIIFEGVRGSGY) and CACHD1 
(KSPYVDDMGAIGDEVITL) with recombinant BACE1, 
without BACE1 or with BACE1 in the presence of the 
BACE1 inhibitor C3 (Figure 4). Separation of the peptide 
and its cleaved fragments was done by nano liquid chro-
matography followed by LC-MS/MS analysis. For both 
peptides, BACE1-dependent cleavage products were iden-
tified which were not detected or strongly reduced when 
BACE1 was inhibited or absent. The PINPSGPFQIIF pep-
tide representing the N-terminal cleavage product of the 
MDGA1 peptide was detected upon BACE1 application 
which was strongly reduced upon inhibition with C3 (Figure 
4A). For CACHD1, we have identified the N-terminal 
F I G U R E  4  BACE1 cleavage site determination of MDGA1 (A) and CACHD1 (B). In the sequence views, peptides close to the cell 
membrane that were chosen for an in-vitro cleavage assay are indicated in bold black letters. The GPI-anchor amidated serine of MDGA1 and 
the transmembrane region of CACHD1 are highlighted with bold purple letters. The two peptides were incubated with recombinant BACE1, with 
BACE1 and its inhibitor C3, or without BACE1. The corresponding extracted ion chromatograms of the full-length peptides (FL) as well as the 
identified cleavage products are presented in a stacked view (red: BACE1, blue: BACE1 + C3 inhibitor, cyan: without BACE1). For MDGA1, 
an N-terminal cleavage product was detected which was strongly reduced upon BACE1 inhibition or in its absence. Similarly, for CACHD1, an 
N-terminal and a C-terminal cleavage product were identified, as well as the oxidized (Ox) N-terminal product that all showed a strong intensity 
decrease when BACE1 was inhibited by C3 whereas almost no signal was detected if BACE1 was absent. Full-length protein was also detected in 
its oxidized form (Ox FL). The N-terminal cleavage products were identified by fragment ion spectra with high mass accuracy and high ion scores. 
The determined cleavage sites are indicated in the sequence views
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cleavage product KSPYVDDMGAIGD as well as the 
C-terminal cleavage product EVITL, which was strongly 
reduced when BACE1 was inhibited (Figure 4B). For both 
MDGA1 and CACHD1 the cleavage site has the acidic 
amino acid glutamate (E) at the P1′ site (the amino acid 
C-terminal to the cleavage site). A glutamate at the same 
position is also found in another BACE1 substrate, seizure 
6-like protein (SEZ6L), and the equally acidic amino acid 
aspartate is found in the additional BACE1 substrates APP 
and SEZ6.11,47,66 Thus at the P1’ site the newly identified 
cleavage sites are in agreement with cleavage sites identi-
fied in other substrates. For the amino acid at the P1 site 
(directly N-terminal to the cleavage site) MDGA1 has phe-
nylalanine, which is hydrophobic, similar to leucine that is 
found at this position in other BACE1 substrates, such as 
SEZ6 and the Swedish mutant of APP.47,66 For CACHD1 
the P1 amino acid is aspartate, which has not been observed 
at this position in other BACE1 substrates. However, for 
most BACE1 substrates the cleavage sites have not yet been 
identified and an in vitro BACE1 cleavage study using de-
cameric peptides revealed that BACE1 in general has a 
loose sequence specificity,66 so that there is no common 
cleavage signature motif for this protease. In conclusion, 
these data identify the BACE1 cleavage site of MDGA1 be-
tween phenylalanine893 and glutamate894 and CACHD1 
between aspartate1097 and glutamate1098 (Figure 4).
3.4 | BACE inhibition affects inhibitory 
synaptic transmission
Among other phenotypes, BACE1 KO mice present with re-
duced inhibitory transmission in the hippocampus, but ex-
citatory transmission is affected as well.29,67 While it is not 
yet exactly clear which BACE1 substrates contribute to these 
phenotypes, it is interesting that several BACE1 substrates 
and substrate candidates have a function in synaptic transmis-
sion. This includes SEZ6,27,28 Neuroligin-2 (NLGN2),68 and 
our newly identified BACE1 substrate MDGA1.69 Notably 
NLGN2 and MDGA1 bind each other at inhibitory synapses 
but have opposite effects on inhibitory synapse formation and 
maintenance. It is not known whether the mildly increased 
levels of MDGA1 observed in BACE1 KO brains would be 
sufficient to reduce inhibitory synapse formation and func-
tion. Given that one phenotype, retina degeneration, was 
previously reported in only one BACE1 KO mouse line,70 
but was not obviously seen in the BACE1 KO mouse line 
used here (Figures S3 and S4), we used a pharmacological 
approach to test whether the reported reduction in inhibitory 
synaptic transmission previously reported for one BACE1 
KO mouse line67 is also seen with pharmacological BACE1 
inhibition. To test the effects of BACE1 inhibition on mIP-
SCs, we used primary hippocampal WT mouse neurons 
(Figure 5A-C) as well as organotypic hippocampal tissue 
cultures containing the entorhinal cortex and hippocampus 
from WT mice (Figure 5D-F) and blocked BACE1 with the 
inhibitor C3. In agreement with the previous BACE1 KO 
study,67 inhibition of BACE1 reduced the frequency, but not 
the amplitude of mIPSCs. This demonstrates that the role of 
BACE1 on inhibitory currents is independent of the mouse 
line used and is preserved both in dissociated hippocampal 
neurons as well as in neurons from organotypic cultures with 
intact hippocampal connectivity.
4 |  DISCUSSION
The protease BACE1 has major functions in the nervous 
systems as revealed by studies of BACE1-deficient mice.39 
Because the function of a protease is determined by its sub-
strates, it is essential to identify BACE1 substrates, their re-
spective function and how these are modulated by BACE1. 
While this was previously achieved for some BACE1 sub-
strates, the functional consequence of the BACE1 cleavage 
of other substrates is not yet established. Moreover, numer-
ous additional membrane proteins were identified as BACE1 
substrate candidates, mostly by proteomic studies, but not yet 
validated. With proteomic and biochemical analysis of mouse 
brains and primary neurons, our study adds the two mem-
brane proteins MDGA1 and CACHD1 to the growing list of 
BACE1 substrates that are validated in vitro and in vivo.
MDGA1 has diverse functions, for example as a cell 
adhesion protein in migration and positioning of a subset 
of neurons in the cortex during mouse development.71,72 
Another function that is well understood at the molecular 
and structural level, is its role as a negative regulator of 
trans-synaptic cell adhesion across inhibitory synapses.73-75 
MDGA1 selectively binds neuroligin-2 (NLGN2) in cis at 
the postsynapse and thereby prevents NLGN2 from estab-
lishing firm trans-synaptic interactions with a presynaptic 
neurexin. Thus, MDGA1 and NLGN2 have opposite func-
tions in inhibitory synapse formation. As a consequence, 
overexpression of MDGA1 reduced the number of inhibi-
tory synapses in cultured hippocampal neurons, resulting 
in reduced frequency of mIPSCs, with the amplitude of 
the currents not being affected.73,74 Conversely, MDGA1-
deficiency in mice induced increased inhibitory synapse 
formation in the hippocampus and increased mIPSC fre-
quency with no change of the amplitude.73-75 This estab-
lished function of MDGA1 is attributed to full-length 
MDGA1, but the crystal structures of MDGA1 bound to 
NLGN2 were obtained with the recombinant, soluble ecto-
domains of both proteins.76,77 Thus, it appears possible that 
not only full-length, but also the BACE1-cleaved soluble 
MDGA1 may bind to NLGN2 in vivo and affect the binding 
of NLGN2 to neurexins. Interestingly, NLGN2 itself has 
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been suggested as a BACE1 substrate candidate, but not 
yet been validated.11 Given the potentially multiple inter-
actions between MDGA1 and NLGN2, it remains unclear 
how BACE1 affects the opposite functions of MDGA1 and 
NLGN2 in inhibitory synaptic transmission. On the one 
hand, it may be speculated that the mildly increased levels 
of MDGA1 observed in BACE1 KO brains may be suffi-
cient to reduce inhibitory synapse formation and function. 
This would be consistent with the reduced inhibitory post-
synaptic currents upon BACE1 inhibition in hippocampal 
neurons from dissociated cultures as well as organotypic 
hippocampal slices, as observed here and previously in 
acute hippocampal slices from BACE1 KOs.67 On the other 
hand, though, the levels of the substrate candidate NLGN2 
would be expected to be increased as well and may seques-
ter the increased MDGA1 levels, thus not resulting in a 
change in inhibitory synapse formation. Yet, other BACE1 
substrates, such as SEZ6, voltage-gated sodium channels, 
Jagged, and Nrg1, also affect directly or indirectly synap-
tic transmission.25-28,32,78,79 Thus, synaptic alterations in 
BACE1-deficent mice may not be attributed easily to indi-
vidual substrates, but may reflect complex changes in the 
function of multiple substrates.
The second validated BACE1 substrate in our study is 
CACHD1. Two very recent studies provided the first bio-
chemical and functional characterization of CACHD1, using 
overexpression of CACHD1 in kidney and neuroblastoma 
cell lines and in hippocampal neurons. They demonstrate 
F I G U R E  5  Pharmacological 
inhibition of BACE1 decreases the 
frequency of miniature inhibitory 
postsynaptic currents in dissociated cultured 
hippocampal neurons and in hippocampal 
neurons from organotypic hippocampal 
slices. A and D, Representative traces of 
mIPSCs from neurons pretreated with 
DMSO (control) in black and BACE 
inhibitor (C3) in blue, in dissociated 
cultured hippocampal neurons (A) and in 
CA1 pyramidal neurons from entorhino-
hippocampal slice cultures (D), respectively. 
B, E and C, F, Mean mIPSC frequencies 
and mIPSC amplitude of the neurons 
pretreated with BACE inhibitor (C3, blue) 
and (DMSO, black), respectively. Note 
the significant decrease in the mIPSC 
frequencies of C3 treated neurons (B, E). 
Data in (B, C) were obtained from n = 26-
28 neurons in 3-4 independent experiments. 
Data in (E, F) were obtained from n = 27 
neurons and their statistical analysis were 
performed using unpaired t test with the 
significance criteria of P < .05. Graphs are 
presented with mean ± SEM
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that CACHD1 closely interacts with voltage-gated calcium 
channels of the N-type58 and T-type59 at the cell surface and 
enhances the densities of their calcium currents. Both studies 
suggest that CACHD1 may be acting as a new auxiliary sub-
unit of voltage-activated N- and T-type calcium channels. This 
is reminiscent of the known function of a CACHD1 homolog, 
α2δ, a known auxiliary subunit of Cav1 and Cav2 channels.80 
Despite functional similarities, CACHD1 and α2δ also have 
distinct features and one of them involves their proteolytic 
processing. After biosynthesis, the GPI-anchored protein α2δ 
undergoes proteolytic maturation, where an as yet unknown 
protease cleaves within the ectodomain of α2δ, yielding the 
α2 and the δ subunit which remain linked as a heterodimer 
through disulfide bridges.81,82 Similar proteolytic heterodi-
mer formations with or without disulfide bridges are known 
for other membrane proteins, such as Notch,83 NrCAM,84 and 
the insulin receptor.85,86 While evidence for proteolytic pro-
cessing of CACHD1 was not reported in the two recent func-
tional studies,58,59 our study demonstrates CACHD1 cleavage 
by BACE1. Compared to α2δ, where the proteolytic cleavage 
site in the ectodomain is more than 100 amino acids away 
from the transmembrane domain (according to Uniprot), the 
cleavage site in CACHD1 was found to be at a distance of 
only 12 amino acids from the membrane. Given that the sol-
uble CACHD1 ectodomain arising through BACE1 cleavage 
is found in the conditioned medium of cultured cell lines and 
primary neurons (this study and11), it appears unlikely that 
it forms a heterodimer with the CACHD1 CTF in a manner 
comparable to α2δ. Instead, BACE1 cleavage of CACHD1 
looks like a typical example of ectodomain shedding of mem-
brane proteins,1 which may serve different molecular func-
tions, such as the termination of the function of a full-length 
membrane protein. Thus, it appears possible that BACE1 
cleavage is a mechanism to control CACHD1’s function in 
calcium signaling and synaptic transmission.58,59
Yet, other functional scenarios also appear possible for 
the BACE1 cleavage of CACHD1. The BACE1-cleaved 
sCACHD1 ectodomain may have an as yet unknown phys-
iological function, similar to what was reported for other 
membrane proteins, such as death receptor 6 (DR6), where 
the full-length membrane protein acts as a receptor con-
trolling cell death, but the cleaved ectodomain acts as a 
cytokine suppressing myelination.87 Importantly, similar 
to numerous other type I membrane proteins,88 we found 
that CACHD1 is not only subject to ectodomain shedding 
by BACE1, but also to subsequent cleavage by γ-secretase, 
which generates additional cleavage products, such as the 
intracellular domain that may itself have a role in signal 
transduction and gene regulation, as it is established for the 
Notch receptor.89 Whether γ-secretase cleavage of CACHD1 
also leads to functional cleavage products or is merely a way 
to degrade the membrane-bound CACHD1 CTF, remains to 
be determined.
Another outcome of our study relates to proteomic strat-
egies for identifying BACE1 substrates. Full-length protein 
levels of MDGA1 and CACHD1 were only mildly increased 
(less than 30%) in the cell lysate or the brain membrane frac-
tion upon BACE1-deficiency. In contrast, in the conditioned 
medium the reduction of the cleaved, secreted ectodomain 
was much more prominent with a 60%-70% decrease for 
MDGA1 and an 80% decrease for CACHD1. Similar ob-
servations were made in our initial proteomic mouse brain 
analysis, where most detected BACE1 substrates, such as 
APP or APLP2, showed a modest increase of less than two-
fold of their full-length protein levels in the BACE1 KO 
brain membrane fraction, with only two proteins (CHL1, 
contactin-2) showing an increase larger than twofold. 
Likewise, a previous study determining changes of the neu-
ronal surface membrane proteome upon pharmacological 
BACE1 inhibition reported a less than twofold increase for 
most BACE1 substrates,90 demonstrating that the effect size 
of the enrichment of full-length BACE1 substrates in the 
lysate or membrane is relatively small upon BACE1 inhi-
bition or deficiency. In contrast, previous proteomic studies 
analyzing changes of the cleaved ectodomains of BACE1 
substrates in the conditioned medium of cells or in the cere-
brospinal fluid reported larger fold changes,11,12,15,47 similar 
to our observation here with MDGA1 and CACHD1. Thus, 
for potential future BACE1 substrate identification screens, 
it appears preferable to measure the larger changes in the 
levels of the cleaved substrate ectodomains rather than the 
smaller changes of the full-length proteins in the lysates or 
membranes.
Taken together, our study adds MDGA1 and CACHD1 
to the growing list of validated BACE1 substrates. This 
has implications for both basic and disease-related neu-
roscience. Given that MDGA1 and CACHD1 have fun-
damental functions in inhibitory synapse formation and 
voltage-gated calcium channel signaling, respectively, it 
appears possible that BACE1 modulates both processes, 
but its exact role needs to be elucidated in more detail. 
Interestingly, MDGA1 has been genetically linked to psy-
chiatric diseases, such as schizophrenia and bipolar disor-
der.91,92 Notably, several psychiatric side effects, such as 
suicidal ideation, anxiety, psychotic symptoms, and de-
pression were also reported for a small percentage of in-
dividuals treated with BACE1-targeted inhibitors in phase 
3 trials of AD.21,22 Moreover, BACE1-deficient mice show 
several defects in the nervous system, such as epileptic 
seizures and schizophrenic symptoms. While it is not yet 
known which in vivo BACE1 substrates contribute to what 
extent to the observed phenotypes, the continued identifi-
cation and validation of BACE1 substrates is an import-
ant step toward a comprehensive understanding of in vivo 
BACE1 functions at the molecular level and of side effects 
occurring in BACE1 clinical trials.
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